| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
38,180,000 |
| Market
Cap: |
56.51(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$1.48 - $1.98 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile TCR2 Therapeutics is a clinical-stage cell therapy company developing T cell therapies for cancer patients suffering from solid tumors by powering the T cell receptor (TCR) with its TCR Fusion Construct T cells (TRuC-T cells). Co.'s TRuC-T cells recognize and kill cancer cells by using the entire TCR signaling complex. Co.'s TRuC-T cell targeting mesothelin-expressing solid tumors are: gavocabtagene autoleucel, in which Co. is conducting its clinical trial to treat patients with non-small cell lung cancer, ovarian cancer, malignant pleural/peritoneal mesothelioma or cholangiocarcinoma; and TC-510, which incorporates a PD-1:CD28 chimeric switch receptor.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
121,863 |
468,513 |
| Total Buy Value |
$0 |
$0 |
$226,133 |
$885,368 |
| Total People Bought |
0 |
0 |
1 |
1 |
| Total Buy Transactions |
0 |
0 |
5 |
9 |
| Total Shares Sold |
0 |
0 |
140,340 |
287,401 |
| Total Sell Value |
$0 |
$0 |
$263,840 |
$445,404 |
| Total People Sold |
0 |
0 |
2 |
6 |
| Total Sell Transactions |
0 |
0 |
2 |
33 |
| End Date |
2024-02-08 |
2023-11-07 |
2023-05-09 |
2022-05-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Menzel Garry E |
President & CEO |
• • – |
2022-12-02 |
4 |
AS |
$1.39 |
$11,687 |
D/D |
(8,408) |
212,650 |
|
11% |
|
| Olagunju Peter |
Chief Technical Officer |
• – – |
2022-12-02 |
4 |
AS |
$1.39 |
$1,766 |
D/D |
(1,273) |
34,328 |
|
11% |
|
| Justice Angela |
Chief People Officer |
• – – |
2022-12-02 |
4 |
AS |
$1.39 |
$3,162 |
D/D |
(2,273) |
66,996 |
|
11% |
|
| Cardama Alfonso Quintas |
Chief Medical Officer |
• – – |
2022-12-02 |
4 |
AS |
$1.39 |
$5,054 |
D/D |
(3,636) |
138,664 |
|
11% |
|
| Menzel Garry E |
President & CEO |
• • – |
2022-12-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
221,058 |
221,058 |
|
- |
|
| Olagunju Peter |
Chief Technical Officer |
• – – |
2022-12-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
33,409 |
35,601 |
|
- |
|
| Justice Angela |
Chief People Officer |
• – – |
2022-12-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
59,576 |
69,269 |
|
- |
|
| Cardama Alfonso Quintas |
Chief Medical Officer |
• – – |
2022-12-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
95,385 |
142,300 |
|
- |
|
| Menzel Garry E |
President & CEO |
• • – |
2022-07-05 |
4 |
GA |
$0.00 |
$0 |
I/I |
265,459 |
132,730 |
|
- |
|
| Menzel Garry E |
President & CEO |
• • – |
2022-07-05 |
4 |
GD |
$0.00 |
$0 |
D/D |
180,932 |
0 |
|
- |
|
| Menzel Garry E |
President & CEO |
• • – |
2022-07-05 |
4 |
GD |
$0.00 |
$0 |
I/I |
84,527 |
0 |
|
- |
|
| Justice Angela |
Chief People Officer |
• – – |
2022-02-28 |
4 |
A |
$2.30 |
$5,143 |
D/D |
2,236 |
9,693 |
|
- |
|
| Menzel Garry E |
President & CEO |
• • – |
2022-02-28 |
4 |
A |
$2.30 |
$3,278 |
D/D |
1,425 |
180,932 |
|
- |
|
| Menzel Garry E |
President & CEO |
• • – |
2021-12-09 |
4 |
OE |
$0.74 |
$129,500 |
D/D |
175,000 |
179,507 |
|
- |
|
| Cardama Alfonso Quintas |
Chief Medical Officer |
• – – |
2021-12-09 |
4 |
OE |
$0.74 |
$31,820 |
D/D |
43,000 |
46,915 |
|
- |
|
| Menzel Garry E |
President & CEO |
• • – |
2021-08-31 |
4 |
A |
$14.26 |
$6,018 |
D/D |
422 |
4,507 |
|
- |
|
| Cardama Alfonso Quintas |
Chief Medical Officer |
• – – |
2021-08-31 |
4 |
A |
$14.26 |
$2,339 |
D/D |
164 |
3,915 |
|
- |
|
| Justice Angela |
Chief People Officer |
• – – |
2021-08-31 |
4 |
A |
$14.26 |
$5,405 |
D/D |
379 |
7,457 |
|
- |
|
| Justice Angela |
Chief People Officer |
• – – |
2021-04-02 |
4 |
OE |
$14.81 |
$99,997 |
D/D |
6,752 |
7,078 |
|
- |
|
| Cardama Alfonso Quintas |
Chief Medical Officer |
• – – |
2021-02-28 |
4 |
A |
$16.12 |
$11,416 |
D/D |
708 |
3,751 |
|
- |
|
| Menzel Garry E |
President and CEO |
• • – |
2021-02-28 |
4 |
A |
$16.12 |
$11,061 |
D/D |
686 |
4,085 |
|
- |
|
| Justice Angela |
Chief People Officer |
• – • |
2021-02-28 |
4 |
A |
$16.12 |
$5,257 |
D/D |
326 |
326 |
|
- |
|
| Hofmeister Robert |
Chief Scientific Officer |
• – – |
2020-12-22 |
4 |
OE |
$0.74 |
$5,180 |
D/D |
7,000 |
45,850 |
|
- |
|
| Somaiya Mayur Ian |
Chief Financial Officer |
• – – |
2020-12-14 |
4 |
AS |
$35.00 |
$70,000 |
D/D |
(2,000) |
1,473 |
|
-13% |
|
| Somaiya Mayur Ian |
Chief Financial Officer |
• – – |
2020-12-14 |
4 |
OE |
$5.88 |
$11,760 |
D/D |
2,000 |
3,473 |
|
- |
|
132 Records found
|
|
Page 3 of 6 |
|
|
